MHRA Approval follows European Commission marketing authorization of LUPKYNIS to treat adults with active lupus nephritis in 27 European Union Member States
LUPKYNIS is the first oral medicine approved in the U.S. and Europe for the treatment of adults living with active lupus nephritis
https://finance.yahoo.com/news/aurinia-announces-great-britain-marketing-210500772.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.